ArticleJournal of clinical and translational hepatology2025

Significant Response to Palbociclib Plus Lenvatinib as Second-line Treatment for CDKN2A/2B Deletion Intrahepatic Cholangiocarcinoma: A Case Report.

Kai Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.